Technical Analysis for TRVN - Trevena, Inc.

Grade Last Price % Change Price Change
F 1.75 -12.06% -0.24
TRVN closed down 12.06 percent on Friday, November 1, 2024, on 12 percent of normal volume.
Earnings due: Nov 12
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion -12.06%
Gapped Down Weakness -12.06%
Doji - Bearish? Reversal -21.52%
Wide Bands Range Expansion -21.52%
Gapped Up Strength -21.52%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -9.33%
Calm After Storm Range Contraction -9.33%
Outside Day Range Expansion -9.33%

   Recent Intraday Alerts

Alert Time
Down 3% 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
Rose Above Previous Day's High 3 days ago
Up 5% 3 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Trevena, Inc. Description

Trevena, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing therapeutics for G protein coupled receptors. Its products include TRV027 that has completed Phase 2a clinical trials for the treatment of acute heart failure; TRV130, a small molecule G protein biased ligand at the µ-opioid receptor has completed Phase 1b clinical trials to treat moderate to severe acute pain intravenously; TRV734 that is in preclinical studies as a orally administered treatment of moderate to severe acute and chronic pain; and d-opioid receptor G protein biased ligand therapeutics for the treatment of central nervous system disorders. The company was formerly known as Parallax Therapeutics, Inc. and changed its name to Trevena, Inc. in January 2008. Trevena, Inc. was founded in 2007 and is based in King of Prussia, Pennsylvania.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Organic Compounds Opioids Chronic Pain Heart Failure Central Nervous System Disorders Signal Transduction Analgesics Nervous System Disorders Acute Pain Pyridines Cell Signaling Acute And Chronic Pain Treatment Of Central Nervous System Disorders Opioid Receptors

Is TRVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.2325
52 Week Low 1.13
Average Volume 49,974
200-Day Moving Average 9.43
50-Day Moving Average 4.19
20-Day Moving Average 3.21
10-Day Moving Average 2.46
Average True Range 0.65
RSI (14) 36.31
ADX 24.17
+DI 16.76
-DI 35.86
Chandelier Exit (Long, 3 ATRs) 3.49
Chandelier Exit (Short, 3 ATRs) 3.07
Upper Bollinger Bands 5.28
Lower Bollinger Band 1.13
Percent B (%b) 0.15
BandWidth 129.31
MACD Line -0.77
MACD Signal Line -0.63
MACD Histogram -0.14
Fundamentals Value
Market Cap 30.26 Million
Num Shares 17.3 Million
EPS -2.64
Price-to-Earnings (P/E) Ratio -0.66
Price-to-Sales 3.16
Price-to-Book 2.85
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.20
Resistance 3 (R3) 2.25 2.15 2.13
Resistance 2 (R2) 2.15 2.04 2.13 2.10
Resistance 1 (R1) 1.95 1.96 1.90 1.90 2.07
Pivot Point 1.85 1.85 1.83 1.83 1.85
Support 1 (S1) 1.65 1.74 1.60 1.60 1.43
Support 2 (S2) 1.55 1.66 1.53 1.40
Support 3 (S3) 1.35 1.55 1.38
Support 4 (S4) 1.30